Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Yang Website

James C. Yang, M.D.

Selected Publications

1)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
[Journal]
2)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. [Epub ahead of print], 2013.
[Journal]
3)  Yang JC.
The adoptive transfer of cultured T cells for patients with metastatic melanoma.
Clin. Dermatol. 31: 209-19, 2013.
[Journal]
4)  Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.
Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
Cancer Res. 72: 6119-29, 2012.
[Journal]
5)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
6)  Economou J, Yang J, Tomlinson J.
Townsend, Jr. C, Beauchamp R, Evers B, Mattox K, eds.
Tumor Immunology and Immunotherapy. In: Sabiston Textbook of Surgery. Volume 19th Edition.
Philadelphia: W.B. Saunders; 2012. p. Section 5, Chapter 31 [Book Chapter]
7)  Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ.
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma.
Otolaryngol Head Neck Surg. 147: 744-9, 2012.
[Journal]
8)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
[Journal]
9)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
[Journal]
10)  Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A.
αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
Immunity. 36: 79-91, 2012.
[Journal]
11)  Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME.
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
J. Immunother. 35: 400-8, 2012.
[Journal]
12)  Linehan W, Rini B, Yang J.
DeVita, Jr. V, Lawrence T, Rosenberg S, eds.
Cancer of the Kidney. In: Principles & Practice of Oncology. Volume Ninth Edition.
Philadelphia: Lippincott, Williams and Wilkins; 2011. p. 1161-82 [Book Chapter]
13)  Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Proc. Natl. Acad. Sci. U S A. 108: E323-31, 2011.
[Journal]
14)  Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC.
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
J. Immunother. 34: 397-402, 2011.
[Journal]
15)  Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC.
Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
J. Immunol. Methods. 366: 43-51, 2011.
[Journal]
16)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
Clin Cancer Res. 17: 4550-7, 2011.
[Journal]
17)  Yang JC.
Melanoma vaccines.
Cancer J. 17: 277-82, 2011.
[Journal]
18)  Hanada K, Wang QJ, Inozume T, Yang JC.
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Blood. 117: 4816-25, 2011.
[Journal]
19)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
[Journal]
20)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
[Journal]
21)  Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Mol. Ther. 18: 843-51, 2010.
[Journal]
22)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Clin. Cancer Res. 16: 6122-31, 2010.
[Journal]
23)  Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
J. Immunother. 33: 626-9, 2010.
[Journal]
24)  Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Ann. Surg. Oncol. 17: 163-70, 2010.
[Journal]
25)  Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA.
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
J. Immunother. 33: 828-33, 2010.
[Journal]
26)  Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross SB, Morgan RA, Cornetta K, Rosenberg SA.
Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles using a.
Hum. Gene Ther. 22: 107-15, 2010.
[Journal]
27)  Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC.
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
J. Immunother. 33: 956-64, 2010.
[Journal]
28)  Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM.
Successful treatment of melanoma brain metastases with adoptive cell therapy.
Clin. Cancer Res. 16: 4892-8, 2010.
[Journal]
29)  Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC.
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
J. Immunother. 33: 840-7, 2010.
[Journal]
30)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CR, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Vanwaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 114: 535-46, 2009.
[Journal]
31)  Inozume T, Hanada K, Wang QJ, Yang JC.
IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells.
J. Immunother. 32: 109-17, 2009.
[Journal]
32)  Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB.
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology. 116: 981-989.e1, 2009.
[Journal]
33)  Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE.
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.
Cancer J. 15: 441-7, 2009.
[Journal]
34)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens.
J. Clin. Oncol. 26: 5233-9, 2008.
[Journal]
35)  Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat. Rev. Cancer. 8: 299-308, 2008.
[Journal]
36)  Stein WD, Yang J, Bates SE, Fojo T.
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
Oncologist. 13: 1055-62, 2008.
[Journal]
37)  Wang QJ, Hanada K, Yang JC.
Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas.
J. Immunol. 181: 3769-76, 2008.
[Journal]
38)  Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S.
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Cancer. 113: 293-301, 2008.
[Journal]
39)  Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, Abdul T, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW.
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.
J. Clin. Invest. 118: 1099-109, 2008.
[Journal]
40)  Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin. Cancer Res. 14: 5610-8, 2008.
[Journal]
41)  Yang JC.
Vitespen: a vaccine for renal cancer?.
Lancet. 372: 92-3, 2008.
[Journal]
42)  Linehan M, Rini B, Yang J.
Cancer of the Kidney. In: Principles & Practice of Oncology. Volume Eighth Edition.
Philadelphia: Lippincott, Williams and Wilkins; 2007. In Press. [Book Chapter]
43)  Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA.
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
J. Immunother. 30: 825-30, 2007.
[Journal]
44)  Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clin. Cancer Res. 13: 6681-8, 2007.
[Journal]
45)  Yang J.
CTLA4 blockade and regulatory T-cells: cause, effect or non sequitur?.
J Clin Oncol. 2006.
In Press. [Journal]
46)  Kerwshaw M, Westwood J, Parker L, Wang G, Eshhar Z, Mavroukakis S, White D, Wunderlich J, Canevari S, Rogers-Freezer L, Chen C, Yang J, Rosenberg S, Hwu P.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clin. Cancer Res. 12: 6106-15, 2006.
[Journal]
47)  Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
J. Immunother. 29: 224-31, 2006.
[Journal]
48)  Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R, Royal R, Topalian S, Kammula U, Restifo N, Zheng Z, Nahvi A, de Vries C, Rogers-Freezer L, Mavroukakis S, Rosenberg S.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science. 314: 126-9, 2006.
[Journal]
49)  Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC.
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-9, 2006.
[Journal]
50)  Yang J, Childs R.
Immunotherapy for renal cell cancer.
J. Clin. Oncol. 24: 5576-83, 2006.
[Journal]
51)  Maker A, Yang J, Sherry R, Topalian S, Kammula U, Royal R, Hughes M, Yellin M, Haworth L, Levy C, Allen T, Mavroukakis S, Attia P, Rosenberg S.
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
J Immunother. 29: 455-63, 2006.
[Journal]
52)  Yang JC, Abad J, Sherry R.
Treatment of oligometastases after successful immunotherapy.
Semin. Radiat. Oncol. 16: 131-5, 2006.
[Journal]
53)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol. 23: 2346-57, 2005.
[Journal]
54)  Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J. Clin. Oncol. 23: 6043-53, 2005.
[Journal]
55)  Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
J. Immunother. 28: 593-8, 2005.
[Journal]
56)  Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC.
Generating renal cancer-reactive T-cells using dendritic cells (DCs) to present autologous tumor.
J. Immunother. 28: 551-9, 2005.
[Journal]
57)  Hanada K, Yang JC.
Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.
J. Mol. Med. 83: 420-8, 2005.
[Journal]
58)  Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
J. Immunol. 175: 6169-76, 2005.
[Journal]
59)  Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Ann. Surg. Oncol. 12: 1005-16, 2005.
[Journal]
60)  Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC.
A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
J. Immunother. 27: 259-64, 2004.
[Journal]
61)  Yang JC.
Bevacizumab for patients with metastatic renal cancer: an update.
Clin. Cancer Res. 10: 6367S-70S, 2004.
[Journal]
62)  Rosenberg SA, Yang JC, Restifo NP.
Cancer immunotherapy: moving beyond current vaccines.
Nat. Med. 10: 909-15, 2004.
[Journal]
63)  Hanada K, Yewdell JW, Yang JC.
Immune recognition of a human renal cancer antigen results from post-translational protein splicing.
Nature. 427: 203-4, 2004.
[Journal]
64)  Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
J. Immunother. 27: 472-7, 2004.
[Journal]
65)  Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L.
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Clin. Cancer Res. 10: 6277S-81S, 2004.
[Journal]
66)  Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
J. Immunol. 173: 7209-16, 2004.
[Journal]
67)  Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA.
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N. Engl. J. Med. 349: 427-34, 2003.
[Journal]
68)  Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc. Natl. Acad. Sci. U.S.A. 100: 8372-7, 2003.
[Journal]
69)  Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
J. Immunother. 26: 385-93, 2003.
[Journal]
70)  Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M, Carson JM, Sellers D, Libutti SK, Yang JC, Bacharach SL.
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
Eur J Nucl Med Mol Imaging. 30: 46-53, 2003.
[Journal]
71)  Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
J. Immunother. 26: 349-56, 2003.
[Journal]
72)  Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE.
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Hum. Gene Ther. 14: 709-14, 2003.
[Journal]
73)  Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF, Staudt LM, Thompson TE, Yang JC.
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Clin. Adv. Hematol. Oncol. 1: 302-6, 2003.
[Journal]
74)  Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA.
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
J. Clin. Oncol. 21: 3127-32, 2003.
[Journal]
75)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clin. Cancer Res. 9: 2973-80, 2003.
[Journal]
76)  Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA.
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
J Immunother. 25: 243-51, 2002.
[Journal]
77)  Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science. 298: 850-4, 2002.
[Journal]
78)  Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF.
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.
J Clin Invest. 109: 1463-70, 2002.
[Journal]
79)  Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA.
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
J Clin Oncol. 20: 142-52, 2002.
[Journal]
80)  Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK.
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Cancer. 95: 1637-43, 2002.
[Journal]
81)  Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ.
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.
J Immunother. 25: 82-7, 2002.
[Journal]
82)  Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA.
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
J Immunother. 24: 363-73, 2001.
[Journal]
83)  Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC.
Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.
Cancer Res. 61: 5511-6, 2001.
[Journal]
84)  Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P.
Immunization against endogenous retroviral tumor-associated antigens.
Cancer Res. 61: 7920-4, 2001.
[Journal]
85)  Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
J Urol. 166: 68-72, 2001.
[Journal]
86)  Feldman AL, Pak H, Yang JC, Alexander HR, Libutti SK.
Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Cancer. 91: 1525-9, 2001.
[Journal]
87)  Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Libutti SK.
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Clin Cancer Res. 6: 4628-34, 2000.
[Journal]
88)  Yang JC, Perry-Lalley D.
The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors.
J Immunother. 23: 177-83, 2000.
[Journal]
89)  Ladányi A, Nishimura MI, Rosenberg SA, Yang JC.
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
J Immunother. 23: 36-47, 2000.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 9/16/2013.